Search Result

Results for "

somatostatin receptor

" in MCE Product Catalog:

By Targets:	Somatostatin Receptor (40) Adenylate Cyclase (2) Apoptosis (2) Bombesin Receptor (1) CRFR (1) Dopamine Receptor (1) Opioid Receptor (2) Urotensin Receptor (2)
By Research Areas:	Cancer (14) Cardiovascular Disease (7) Endocrinology (21) Inflammation/Immunology (6) Metabolic Disease (7) Neurological Disease (18)

Inhibitors & Agonists

Peptides

Recombinant Proteins

Targets Recommended: Somatostatin Receptor

Cat. No.	Product Name	Target	Research Areas

HY-108498

L-817818	Somatostatin Receptor	Endocrinology
L-817818 is a potent and subtype-selective agonist of the **somatostatin receptor*. L-817818 provides a direct approach to defining somatostatin* receptor physiological functions

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cancer Endocrinology Inflammation/Immunology Cardiovascular Disease
Octreotide (SMS 201-995) pamoate is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly.

HY-P0036

Octreotide SMS 201-995	Somatostatin Receptor Apoptosis	Cancer Endocrinology Inflammation/Immunology Cardiovascular Disease
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly.

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-P1335A

CTAP TFA	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-111615

J-2156	Somatostatin Receptor	Neurological Disease
J-2156 is a high potent, selective **somatostatin receptor type 4 (SST4 receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST4 receptors*, respectively. J-2156 is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.

HY-111615A

J-2156 TFA	Somatostatin Receptor	Inflammation/Immunology Neurological Disease
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.

HY-P3954

Somatostatin-28 (sheep)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a **somatostatin receptor antagonist with K_i*s of 6, 17, 66, 1000 and 1000 nM for human somatostatin* receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively).

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-109155

Paltusotine CRN00808	Somatostatin Receptor	Endocrinology
Paltusotine (CRN00808) is an orally active, nonpeptide selective **somatostatin type 2 (SST2) receptor** agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1932

Cortistatin-14	Somatostatin Receptor	Inflammation/Immunology Neurological Disease Endocrinology
Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Inflammation/Immunology Neurological Disease Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

HY-125382

L-797591
Somatostatin Receptor Metabolic Disease

L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist.

L-797591	Somatostatin Receptor	Metabolic Disease
L-797591 is a selective somatostatin receptor subtype 1 (SSTR1) agonist.

HY-108497

L-803087	Somatostatin Receptor	Cancer Neurological Disease
L-803087 is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 is >280-fold higher than other somatostatin receptors. L-803087 facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.

HY-108497A

L-803087 TFA	Somatostatin Receptor	Cancer Neurological Disease
L-803087 TFA is a potent and selective **somatostatin sst4 receptor agonist with a K_i** of 0.7 nM. L-803087 TFA is >280-fold more selective for sst4 receptor than other somatostatin receptors. L-803087 TFA facilitates AMPA-mediated hippocampal synaptic responses in vitro and increases kainate-induced seizures in mice.

HY-P4452

PRL 2915
Somatostatin Receptor Urotensin Receptor Endocrinology

PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM.

PRL 2915	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM.

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Cancer Endocrinology
Veldoreotide (DG3173) a somatostatin analogue, that can bind to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P4100

Cyclic SSTR agonist octreotide
Somatostatin Receptor Others

Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor SSTR agonist.

Cyclic SSTR agonist octreotide	Somatostatin Receptor	Others
Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic **Somatostatin Receptor SSTR** agonist.

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively.

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively.

HY-79135

Pasireotide ditrifluoroacetate SOM230 ditrifluoroacetate; Pasireotide TFA salt	Somatostatin Receptor	Endocrinology Cancer
Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-16381B

Pasireotide (diaspartate) SOM230 (diaspartate)	Somatostatin Receptor	Cancer Neurological Disease
Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-108768

Pasireotide pamoate SOM230 pamoate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors.

HY-79136

Pasireotide L-aspartate salt SOM230 L-aspartate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-102037

SSTR5 antagonist 1	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 1 (compound 25a) is a selective and orally available somatostatin receptor subtype 5 (SSTR5) antagonist with IC₅₀s of 9.6 and 57 nM for hSSTR5 and mSSTR5, respectively.

HY-110161

sst2 Receptor agonist-1	Somatostatin Receptor	Endocrinology Cardiovascular Disease
sst2 Receptor agonist-1 is a potent somatostatin receptor subtype 2 (sst₂) agonist with a K_i value of 0.025 nM and a cAMP IC₅₀ value of 4.8 nM. sst2 Receptor agonist-1 can inhibit rat growth hormone (GH) secretion and ocular neovascular lesion formation. Antiangiogenic effect.

HY-P1212

Cortistatin 14, human, rat CST-14, human, rat	Somatostatin Receptor	Neurological Disease
Cortistatin 14, human, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus.

HY-114191B

SSTR5 antagonist 2 hydrochloride	Somatostatin Receptor	Endocrinology Metabolic Disease
SSTR5 antagonist 2 hydrochloride is a highly potent, oral active and *selective somatostatin* (receptor) subtype 5 (SSTR5)** antagonist and has potential for the research of type 2 diabetes mellitus (T2DM).

HY-16381

Pasireotide SOM230	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-16381A

Pasireotide acetate SOM230 acetate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1202

CYN 154806	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor antagonist, with pIC₅₀** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

HY-114191

SSTR5 antagonist 2	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 antagonist 2 (compound 10) is a highly potent, oral active and *selective somatostatin* (receptor) subtype 5 (SSTR5)** antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).

HY-114191A

SSTR5 antagonist 2 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR5 Antagonist 1 (compound 10) is a highly potent, oral active and *selective somatostatin* (receptor) subtype 5 (SSTR5)** antagonist and has potential for the research of treat type 2 diabetes mellitus (T2DM).

HY-P1202A

CYN 154806 TFA	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM. CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively. CH 275 can be used for the research of alzheimer’s disease.

HY-142699

SSTR4 agonist 2	Somatostatin Receptor	Inflammation/Immunology
SSTR4 agonist 2 is a potent agonist of somatostatin receptor subtype 4 (SSTR4). SSTR4 pathway inhibits nociceptive and inflammatory processes. SSTR4 agonist 2 has the potential for the research of medical disorders related to SSTR4 (extracted from patent WO2014184275A1, compound 107).

HY-103277

BIM 23042	Bombesin Receptor	Metabolic Disease Neurological Disease
BIM 23042, a certain somatostatin (SS) octapeptide analogue, is a selective neuropeptide neuromedin B receptor (NMB-R, BB1) antagonist. BIM 23042 has 100-fold lower affinity for gastrin-releasing peptide (GRP) receptor (BB2). BIM 23042 inhibits Neuromedin B (HY-P0241), ICI 216140 and DPDM-bombesin ethylamide-induced Ca²⁺ release.

HY-P3618

Cortistatin 29	Somatostatin Receptor	Neurological Disease
Cortistatin 29 is a neuropeptide. Cortistatin 29 alleviates neuropathic pain. Cortistatin 29 binds with high affinity all somatostatin (SS) receptor subtypes and shows IC₅₀ values of 2.8, 7.1, 0.2, 3.0, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin 29 shows anti-fibrotic effects.

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research.

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.

HY-P3019

Urocortin III (human)	CRFR	Endocrinology Neurological Disease Cardiovascular Disease
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.

Cat. No.	Product Name	Target	Research Area

HY-P0036B

Octreotide pamoate SMS 201-995 pamoate	Somatostatin Receptor Apoptosis	Cancer Endocrinology Inflammation/Immunology Cardiovascular Disease
Octreotide (SMS 201-995) pamoate is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide pamoate can bind to the **somatostatin receptors which are mainly subtypes 2, 3 and 5. Octreotide pamoate increases Gi activity and reduces intracellular cAMP production. Octreotide pamoate has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly.

HY-P0036

Octreotide SMS 201-995	Somatostatin Receptor Apoptosis	Cancer Endocrinology Inflammation/Immunology Cardiovascular Disease
Octreotide (SMS 201-995) is a **somatostatin receptor** agonist and synthetic octapeptide endogenous somatostatin analogue. Octreotide (SMS 201-995) can bind to the **somatostatin receptor and mainly subtypes 2, 3, and 5, increases Gi activity, and reduces intracellular cAMP production. Octreotide (SMS 201-995) has antitumor activity, mediates apoptosis** and may also be used in disease studies in acromegaly.

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-P1335A

CTAP TFA	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and **somatostatin receptors**. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction.

HY-111615A

J-2156 TFA	Somatostatin Receptor	Inflammation/Immunology Neurological Disease
J-2156 TFA is a high potent, selective **somatostatin receptor type 4 (SST₄ receptor) agonist with IC₅₀*s of 0.05 nM and 0.07 nM for human and rat SST₄ receptors*, respectively. J-2156 TFA has anti-inflammatory activity and it is used for the relief of mechanical allodynia and mechanical hyperalgesia in the ipsilateral hindpaws in rats.

HY-P3954

Somatostatin-28 (sheep)	Somatostatin Receptor	Metabolic Disease
Somatostatin-28 (sheep) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion.

HY-P4469

PRL 3195	Somatostatin Receptor Urotensin Receptor	Cardiovascular Disease
PRL 3195 is a **somatostatin receptor antagonist with K_i*s of 6, 17, 66, 1000 and 1000 nM for human somatostatin* receptors (sst₅, sst₂, sst₃, sst₁ and sst₄, respectively).

HY-P1201

Cyclosomatostatin	Somatostatin Receptor	Cancer
Cyclosomatostatin is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1201A

Cyclosomatostatin TFA	Somatostatin Receptor	Cancer
Cyclosomatostatin TFA is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin TFA can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells.

HY-P1932

Cortistatin-14	Somatostatin Receptor	Inflammation/Immunology Neurological Disease Endocrinology
Cortistatin-14, a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

HY-P1932A

Cortistatin-14 TFA	Somatostatin Receptor	Inflammation/Immunology Neurological Disease Endocrinology
Cortistatin-14 (TFA), a neuropeptide have structural similarity to somatostatin-14, binds and exerts its function via the somatostatin receptors (sst1-sst5). Cortistatin-14 (TFA) shows anticonvulsive, neuroprotective effect and remarkable anti-inflammatory properties.

HY-P4452

PRL 2915
Somatostatin Receptor Urotensin Receptor Endocrinology

PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM.

HY-P0024

Veldoreotide DG3173; PTR-3173	Somatostatin Receptor	Cancer Endocrinology
Veldoreotide (DG3173) a somatostatin analogue, that can bind to and activate the somatostatin receptors (SSTR) 2, 4, and 5. Veldoreotide inhibits growth hormone (GH) secretion in adenomas compared with Octreotide (HY-P0036). Veldoreotide has the potential to be used as pain modulating agent

HY-P4100

Cyclic SSTR agonist octreotide
Somatostatin Receptor Others

Cyclic SSTR agonist octreotide is a Octreotide (HY-P0036), serving as the cyclic Somatostatin Receptor SSTR agonist.

HY-P1203

BIM-23056	Somatostatin Receptor	Neurological Disease
BIM 23056, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively.

HY-P1203A

BIM-23056 TFA	Somatostatin Receptor	Neurological Disease
BIM 23056 TFA, a linear octapeptide, is a potent sst3 and sst5 somatostatin receptor antagonist with K_i values of 10.8, 5.7, respectively.

HY-P3294

Onzigolide BIM-23A760; TBR-760	Dopamine Receptor Somatostatin Receptor	Neurological Disease Cancer
Onzigolide (BIM-23A760), a chimeric dopamine-somatostatin compound, shows potent agonist activity at both DA type 2 (D2R) and SST type 2 (SSTR2) receptors.

HY-P1212

Cortistatin 14, human, rat CST-14, human, rat	Somatostatin Receptor	Neurological Disease
Cortistatin 14, human, rat (CST-14, human, rat), a neuropeptide with neuronal depressant and sleep modulating properties, can bind to all five cloned somatostatin receptors (SSTRs) and ghrelin receptor to exert its biological activities and co-exists with GABA within the cortex and hippocampus.

HY-16381

Pasireotide SOM230	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-16381A

Pasireotide acetate SOM230 acetate	Somatostatin Receptor	Cancer Endocrinology
Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at **somatostatin receptors (subtypes sst1/2/3/4/5, pK_i**=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity.

HY-P1202

CYN 154806	Somatostatin Receptor	Endocrinology
CYN 154806, a cyclic octapeptide, is a potent and selective **somatostatin sst2 receptor antagonist, with pIC₅₀** values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

HY-P3958

BIM-23027	Peptides	Neurological Disease
BIM-23027 is a selective agonist of sst₂ receptor (EC₅₀=0.32 nM), with similar effect to somatostatin (SRIF), a cyclic tetradecapeptide. BIM-23027 stimulates dopamine release, which is mediated by a Glu-dependent mechanism.

HY-P1202A

CYN 154806 TFA	Somatostatin Receptor	Endocrinology
CYN 154806 TFA, a cyclic octapeptide, is a potent and selective somatostatin sst2 receptor antagonist, with pIC₅₀ values of 8.58, 5.41, 6.07, 5.76 and 6.48 for human recombinant sst2, sst1, sst3, sst4 and sst5 receptors respectively.

HY-P1206

CH 275	Somatostatin Receptor	Neurological Disease
CH 275 is a peptide analog of somatostatin and binds preferably to somatostatin receptor 1 (sst₁) with a K_i of 52 nM. CH 275 acts as a potent and selective sst₁ agonist (IC₅₀=30.9 nM) and also displays IC₅₀ values of 345 nM, >1 μM, >10 μM, >10 μM for human sst₃, sst₄, sst₂ and sst₅, respectively. CH 275 can be used for the research of alzheimer’s disease.

HY-P3618

Cortistatin 29	Somatostatin Receptor	Neurological Disease
Cortistatin 29 is a neuropeptide. Cortistatin 29 alleviates neuropathic pain. Cortistatin 29 binds with high affinity all somatostatin (SS) receptor subtypes and shows IC₅₀ values of 2.8, 7.1, 0.2, 3.0, 13.7 nM for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, respectively. Cortistatin 29 shows anti-fibrotic effects.

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research.

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.

HY-P3019

Urocortin III (human)	CRFR	Endocrinology Neurological Disease Cardiovascular Disease
Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) selectively binds to type 2 CRF receptors with K_i values of 13.5, 21.7, and >100 nM for mCRF2β, rCRF2α, and hCRF1, respectively. Urocortin III (human) mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.

Recombinant Proteins Recommended:

Somatostatin Receptor

Cat. No.	Product Name	Species	Source

HY-P700430

SSTR2 Protein-VLP, Human (HEK293, His) SSTR2; somatostatin receptor 2; somatostatin receptor type 2; SS2R; SRIF-1; SS-2-R	Human	HEK293
SSTR2 Protein-VLP, Human (HEK293, His) is recommended for animal immunization, ELISA, FACS. It is not recommended for receptor-ligand interaction detection and SPR/BLI assay since there are other irrelevant membrane proteins of the host on the VLP envelope, and the receptor-ligand interaction will have strong background interference. High requirements for chips and experimental protocols are needed for SPR/BLI assays.